Episode 60
Biotech Hangout
00:00
The Impact of the Debt Ceiling on Drug Revenues
The impact potentially that the increase yield on supposedly riskless instruments like US Treasury bonds, we'll see what happens in June with this debt ceiling. The other thing that I think would be worth mentioning when you mentioned the Pfizer-Seijen debt, which does on the face of it appear like, wow, you're raising very expensive capital to do a transaction. Investors are finally rewarding large pharma companies for doing what are we called pipeline accretive transactions.
Transcript
Play full episode
